Lexeo Therapeutics, Inc. $LXEO Shares Acquired by Montanova Capital LLC

Montanova Capital LLC increased its holdings in shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) by 410.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,384,200 shares of the company’s stock after purchasing an additional 5,134,200 shares during the quarter. Montanova Capital LLC owned approximately 7.78% of Lexeo Therapeutics worth $29,718,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in LXEO. Wellington Management Group LLP increased its stake in Lexeo Therapeutics by 17.2% in the second quarter. Wellington Management Group LLP now owns 202,383 shares of the company’s stock valued at $942,000 after purchasing an additional 29,680 shares during the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $6,051,500. Avoro Capital Advisors LLC acquired a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $6,932,175. Bank of America Corp DE purchased a new position in shares of Lexeo Therapeutics in the 2nd quarter valued at $2,282,000. Finally, Jupiter Topco LLC acquired a new stake in Lexeo Therapeutics during the 2nd quarter worth $18,409,000. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Price Performance

Shares of NASDAQ:LXEO opened at $4.76 on Tuesday. Lexeo Therapeutics, Inc. has a 1-year low of $3.99 and a 1-year high of $10.99. The stock has a market cap of $390.56 million, a P/E ratio of -4.14 and a beta of 1.46. The firm has a fifty day moving average price of $4.74 and a 200 day moving average price of $5.43.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Sell-side analysts expect that Lexeo Therapeutics, Inc. will post -1.18 EPS for the current fiscal year.

Insider Activity

In related news, CEO Richard Nolan Townsend sold 25,947 shares of the business’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the transaction, the chief executive officer owned 377,817 shares in the company, valued at $1,692,620.16. The trade was a 6.43% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Narinder Pal Bhalla sold 22,306 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the sale, the insider directly owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This represents a 21.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 66,326 shares of company stock worth $299,817 in the last 90 days. 2.00% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research firms have issued reports on LXEO. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 13th. Chardan Capital upgraded Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Wall Street Zen downgraded Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Finally, JPMorgan Chase & Co. decreased their target price on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Two analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Lexeo Therapeutics currently has an average rating of “Buy” and an average target price of $18.75.

Lexeo Therapeutics Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.